The Role of Calcipotriol as Radioprotector of Skin
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00445250|
Recruitment Status : Unknown
Verified January 2007 by Rabin Medical Center.
Recruitment status was: Not yet recruiting
First Posted : March 8, 2007
Last Update Posted : March 8, 2007
Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo cutaneous side effect in patients receiving radiotherapy to the breast.
To check the connection between the skin effect of radiotherapy and different parameters including diseases such as diabetes and lupus, use of medications, allergies, weight, habits, size of the irradiated breast, previous chemotherapy treatment and exposure to sunlight.
|Condition or disease||Intervention/treatment||Phase|
|Radiodermatitis||Drug: Calcipotriol||Phase 2|
Fifty women diagnosed with breast cancer planned to receive adjuvant radiotherapy, will participate in the study. About 15 minutes after receiving the daily radiation dose fraction, a cream containing an active vitamin D analogue will be applied to half of the breast with inspection of a nurse. The other half of the breast will have a standard cream applied . During the days that radiotherapy is not administered the standard cream will be applied to both halves of the breast in a case of strong reaction to radiotherapy (e.g. strong erythema, painful tenderness etc.)The adverse skin effects will be assessed according to the following criteria:
. an assessment by a physician and a nurse according to the RTOG score (6).
Grade 0 – no reaction. Grade 1 - light erythema dry peeling, decrease in sweat production. Grade 3 – extensive moist peeling, pitting edema. Grade 4 – ulcers, bleeding and necrosis.
- . A questionnaire to each patient regarding the efficacy and safety of the cream.
- . Number of interruption of radiotherapy treatment. The assessment will be done each week during radiotherapy treatment and weekly for three weeks following the completion of radiotherapy treatment.
Safety report will be sent to the local independent ethics committee after the examination of the first ten patients.
The protective effect of the cream containing calcipotriol will be compared to the standard treatment and analyzed statistically using the parameters mention above. The relation between the background disease, medications, allergies, weight, habits, size of the irradiated breast, sun exposure, previous chemotherapy treatment and exposure to sunlight and the skin reaction will be evaluated.
- . Age ranging from 18 to 75.
- . Confirmed histological diagnosis of Breast cancer.
- . Radiotherapy treatment to the breast following lumpectomy.
- . Scleroderma.
- . An extremely large breast. Interfiled above 25 cm.
- . Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication.
- . Mastectomy.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast.|
- Prevention of radiodermatitis
- Side effects of Calcipotriol
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00445250
|Contact: Eyal Fenig, M.D.||firstname.lastname@example.org|
|Contact: Ofer Purim, M.D.||email@example.com|
|Rabin Medical Center||Not yet recruiting|
|Petach Tiqva, Israel, 49100|
|Contact: Eyal Fenig, M.D. 97239377964 firstname.lastname@example.org|
|Contact: Ofer Purim, M.D. 97239377973 email@example.com|
|Principal Investigator: Eyal Fenig, M.D.|
|Sub-Investigator: Ofer Purim, M.D.|
|Sub-Investigator: Amir Abramovich, M.D.|
|Principal Investigator:||Eyal Fenig, M.D.||Rabin Medical Center|